However, administering anti-PD-1 immunotherapy reinstates the vaccine’s effectiveness, implying that combining ALK vaccines with TKIs and ICIs could present a robust treatment strategy for ALK-driven NSCLC [175]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.